Full Year 2024 Results Key Financial Results Revenue: US$492.0m (up 427% from FY 2023).

REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

Alvotech acquires Xbrane's R&D operations and biosimilar candidate for SEK 275 million, enhancing development capabilities ...

(RTTNews) - Alvotech (ALVO), on Wednesday announced that the UK Medicines and Healthcare Products Regulatory Agency OR MHRA has accepted the marketing authorization application for AVT23 ...

Alvotech Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane ...

Alvotech (NASDAQ:ALVO – Get Free Report) is expected to issue its quarterly earnings data after the market closes on ...

“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...

Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...

Alvotech (ALVO) announced the appointment of Balaji Prasad as chief strategy officer. He was most recently a director and equities analyst at ...

All applications have been subsequently accepted by the relevant regulatory authorities. Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025 ...